Last reviewed · How we verify

Pranoprofen Eyedrops

Università degli Studi di Brescia · FDA-approved active Small molecule

Pranoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis and inflammation in the eye.

Pranoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis and inflammation in the eye. Used for Postoperative inflammation and pain following ocular surgery, Allergic conjunctivitis, Seasonal allergic rhinoconjunctivitis.

At a glance

Generic namePranoprofen Eyedrops
SponsorUniversità degli Studi di Brescia
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase (COX-1, COX-2)
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Mechanism of action

As an NSAID formulated as an ophthalmic solution, pranoprofen works by blocking COX-1 and COX-2 enzymes, thereby decreasing prostaglandin production in ocular tissues. This reduces inflammation, pain, and photophobia associated with various ocular conditions. The drug is applied topically to the eye where it exerts local anti-inflammatory effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: